Home » Topics » Disease categories and therapies » Dermatologic

Dermatologic
RSS

OraDisc A approved for aphthous ulcers

Oct. 7, 2004

Enbrel approved in E.U. for psoriasis

Oct. 5, 2004

Pierre Fabre to commercialize Olux in Europe

Oct. 5, 2004

Approval sought for proof-of-concept study for ATL-1101 in psoriasis

Oct. 4, 2004

European approval for Raptiva for psoriasis

Sep. 30, 2004

Desilux enters phase III program for atopic dermatitis

Sep. 30, 2004

Non-approvable letter for oral tazarotene

Sep. 29, 2004

RegeneRx files to begin phase II study of TB4 for chronic pressure ulcers

Sep. 28, 2004

NF-kappaB Decoy set to enter phase I/II trial in 2005

Sep. 28, 2004

Enrollment completed for U.S. phase II Psoraxine study

Sep. 27, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 7, 2026.
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
Hematopoietic stem cell research points to leukemia’s early roots
BioWorld Science
Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
Infinimmune presents preclinical data on anti-IL-22 antibody for atopic dermatitis
BioWorld Science
Infinimmune Inc. has recently presented results at the annual American Academy of Dermatology conference regarding their anti-IL-22 antibody IFX-101 for the...